Investigator

Yusung Kim

Physics Chief of GU-GYN Section · The University of Texas MD Anderson Cancer Center, Radiation Physics Department

YKYusung Kim
Papers(1)
Iterative intraoperat…
Collaborators(5)
Kyoko Yoshida-CourtMatthew S. NingRamez KouzyShrikiriti S. RajanTravis Sims
Institutions(2)
The University Of Tex…Unknown Institution

Papers

Iterative intraoperative 3T MRI (iMRI)-guided brachytherapy: A prospective study on enhancing implantation precision and dosimetric gains in advanced gynecologic cancers

To report on primary outcomes and dosimetric results of a prospective clinical trial and protocol for use of iterative intraoperative magnetic resonance imaging (iMRI) in gynecologic brachytherapy. Patients with locally advanced cervical or vaginal cancer (FIGO stages IB2 - IVA, and stage II-IVA, respectively) undergoing pulsed dose rate (PDR) brachytherapy were enrolled in a prospective clinical trial (NCT03634267) using iterative 3T iMRI during brachytherapy implant placement. Applicator and optional interstitial needles were placed under iMRI guidance in a 3T clinical MRI scanner. Imaging, dosimetry and clinical outcomes (local control (LC), recurrence-free survival (RFS), overall survival (OS)), and acute and long-term toxicity were evaluated prospectively and confirmed by chart review. To explore dosimetric gains, an EQD2 estimate comparing iMRI-guidance versus standard of care guidance, as well as a 3-patient analysis of dose changes with iMRI-guided optimization was included. Fourteen patients underwent iMRI-guided brachytherapy. Seventy percent (70%) of patients presented with FIGO stage III disease or higher. Median follow-up was 44 months. . Patients had 2-year median LC, RFS, and OS rates of 83.3%, 76%, and 84.6%, respectively. Acute toxicities were minimal with one (1) case of grade 3 nausea. No grade 3 or higher long-term toxicities were observed. Median operating room (OR) time was 283 minutes (range 174-380 mins). On exploratory analysis, implant placement performed with iMRI guidance demonstrated higher HR-CTV D90 doses (mean difference of +784.7 cGy, p = NS) were achieved compared to US and CT guided implantation in the same patients. iMRI-guidance for gynecologic brachytherapy is safe, associated with minimal high-grade toxicity and excellent clinical outcomes. Future studies to optimize resource use, image acquisition efficiency, and identifying predictive imaging features are warranted.

65Works
1Papers
5Collaborators

Positions

2022–

Physics Chief of GU-GYN Section

The University of Texas MD Anderson Cancer Center · Radiation Physics Department

2007–

Brachytherapy Physics Director

The University of Iowa · Radiation Oncology

Education

2007

University of Wisconsin Madison · medical physics

1997

Hanyang University College of Engineering · Nuclear Engineering

Country

US

Links & IDs
0000-0002-8528-4465

Scopus: 55999534000

Researcher Id: S-6731-2018